Daniel Markx

Dr. Daniel Markx joined Boehringer Ingelheim in 2018 as a Post-Doc in the analytical development department, where he mainly dealt with the implementation and development of surface plasmon resonance-based potency assays for customer projects. In 2021 he joined the analytical development of Boehringer-own molecules as a Scientist, and was mainly responsible for the development, validation and transfer of cell-based bioassay. In 2022 he was promoted to a Senior Scientist and takes acts as an analytical project team member discussing the analytical strategy for clinical development.